Cumberland Pharmaceuticals (CPIX) EBIT (2010 - 2026)

Cumberland Pharmaceuticals (CPIX) has 17 years of EBIT data on file, last reported at -$3.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 342.22% year-over-year to -$3.1 million; the trailing twelve-month figure through Mar 2026 stood at -$7.2 million (down 120.51% YoY), and the FY2025 full-year result was -$2.8 million, up 56.59% from the prior year.
• EBIT eased to -$3.1 million in Q1 2026, from -$1.4 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $1.3 million in Q1 2025 to a low of -$6.2 million in Q4 2023.
• A 5-year average of -$1.6 million and a median of -$1.7 million in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT slumped 4591.4% in 2024 and jumped 169.12% in 2025, its largest moves.
• Tracing CPIX's EBIT over 5 years: stood at -$2.3 million in 2022, then plunged by 171.28% to -$6.2 million in 2023, then jumped by 70.19% to -$1.8 million in 2024, then rose by 25.56% to -$1.4 million in 2025, then sank by 128.22% to -$3.1 million in 2026.
• Business Quant data shows CPIX's EBIT at -$3.1 million in Q1 2026, -$1.4 million in Q4 2025, and -$2.0 million in Q3 2025.